Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656681 | 0.91 | HDAC6 (0.51) | HDAC6HDAC1ALDH1A1MAPTHDAC8 | |
| SCHEMBL15480657 | 0.85 | HDAC6 (0.46) | HDAC6HDAC1ALDH1A1MAPTHDAC8 | |
| SCHEMBL4659080 | 0.83 | HDAC6 (0.67) | HDAC6HDAC1ALDH1A1HDAC8HDAC2 | |
| SCHEMBL4659287 | 0.83 | HDAC6 (0.67) | HDAC6HDAC1ALDH1A1HDAC8HDAC2 | |
| SCHEMBL4657802 | 0.82 | HDAC6 (0.64) | HDAC6HDAC1MAPTHDAC8HSD17B1 | |
| SCHEMBL15480654 | 0.81 | HDAC6 (0.72) | HDAC6HDAC1ALDH1A1MAPTHDAC8 | |
| SCHEMBL28869687 | 0.80 | HDAC6 (0.69) | HDAC6HDAC1HDAC8HDAC2NPC1 | |
| SCHEMBL4610487 | 0.80 | HDAC1 (0.61) | HDAC6HDAC1HDAC8HDAC2NPC1 | |
| SCHEMBL15480652 | 0.80 | HDAC6 (0.56) | HDAC6HDAC1HDAC8HDAC2NPC1 | |
| SCHEMBL15482285 | 0.79 | HDAC6 (0.59) | HDAC6HDAC1ALDH1A1MAPTHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660437-B1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2008-10-15 | — | — | EP | claimed |
| US-7282522-B2 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2007-10-16 | — | — | US | claimed |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | US | claimed |
| EP-1660437-A4 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2006-09-20 | — | — | EP | claimed |
| EP-1660437-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | Amorepacific Corporation (KR) | 2006-05-31 | — | — | EP | claimed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | claimed |
| EP-1660437-B1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2008-10-15 | — | — | EP | disclosed |
| US-7282522-B2 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2007-10-16 | — | — | US | disclosed |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | US | disclosed |
| EP-1660437-A4 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2006-09-20 | — | — | EP | disclosed |
| EP-1660437-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | Amorepacific Corporation (KR) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | HDAC7, SIRT7, HCAR1 | HDAC6 201/4885HDAC1 67/4885ALDH1A1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.